{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-007772","form_type":"8-K","ticker":"SEPN","cik":"0001984086","company_name":"Septerna, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.936771+00:00","generated_at":"2026-05-16T11:15:39.825354+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Septerna appoints Mark A. Wilson as Chief Legal Officer, effective January 8, 2026","bullets":["Mark A. Wilson joins from Nektar Therapeutics, where he was SVP and Chief Legal Officer.","He has over 25 years of experience in IP, corporate legal, and strategic collaborations.","Wilson will oversee legal, IP strategy, and governance for Septerna's GPCR drug discovery pipeline.","He previously led global collaborations and patent strategy at Nektar."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-007772","json":"https://secwatch.observer/filing/0001193125-26-007772.json","markdown":"https://secwatch.observer/filing/0001193125-26-007772.md","text":"https://secwatch.observer/filing/0001193125-26-007772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526007772/0001193125-26-007772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526007772/d40604d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:15:39.825354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}